The agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners.
bluebird bio president and CEO Nick Leschly said that Genethon has helped identify the genes responsible for hundreds of diseases, developed vectors for gene transfer therapy and established a GMP manufacturing organization.
Genethon chief executive Frederic Reva said that they look forward to being able to combine their expertise with that of bluebird bio and achieve significant improvements in the production of lentiviral vectors for gene therapy through this collaboration.